Copy to clipboard 
Amplitude Surgical reported FY 4Q22 orthopedic sales of $28.1 million, +25.3% compared to FY 4Q21. For the full fiscal year, the company generated $106.9 million, representing growth of 9.8% vs. the year prior.
The company’s Novastep foot and ankle business continued its steady growth in the fourth quarter and now accounts for about 17% of Amplitude’s total revenue. As the business nears $20 million in annual revenue, it could represent a compelling acquisition opportunity for a larger player.
To that end, Amplitude launched a “strategic review of Novastep’s foot and ankle activity” in late June. The review’s goal is to maximize value creation for the company as a whole and could eventually lead to the divestment of Novastep.
One potential reason for the Novastep review could be Amplitude’s planned entry into robotics. In April, the company partnered with eCential Robotics to develop a robotic knee surgery solution. eCential’s current open system has partnered with multiple players in spine surgery. This partnership will add Amplitude’s proprietary Amplivision navigation and the latest alignment techniques.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $23.3 | $19.1 | $4.2 | 22.1% |
| Knees | $12.8 | $10.3 | $2.5 | 24% |
| Hips | $10.5 | $8.7 | $1.7 | 19.7% |
| Trauma | $4.8 | $3.4 | $1.5 | 43.8% |
| Total | $28.1 | $22.4 | $5.7 | 25.3% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $89.1 | $84.4 | $4.8 | 5.7% |
| Knees | $48.8 | $46.5 | $2.3 | 5% |
| Hips | $40.3 | $37.9 | $2.5 | 6.5% |
| Trauma | $17.8 | $13.1 | $4.7 | 36.2% |
| Total | $106.9 | $97.4 | $9.5 | 9.8% |
Orthopedic Sales by Geography
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $18.3 | $14.3 | $4.0 | 28% |
| International | $9.8 | $8.1 | $1.7 | 20.6% |
| Subsidiaries | $7.2 | $6.1 | $1.1 | 17.4% |
| Distributors | $2.7 | $2.1 | $0.6 | 30.1% |
| Total | $28.1 | $22.4 | $5.7 | 25.3% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $69.6 | $63.6 | $6.0 | 9.4% |
| International | $37.3 | $33.8 | $3.5 | 10.5% |
| Subsidiaries | $28.4 | $25.7 | $2.7 | 10.5% |
| Distributors | $8.9 | $8.1 | $0.8 | 10.5% |
| Total | $106.9 | $97.4 | $9.5 | 9.8% |
Amplitude Surgical reported FY 4Q22 orthopedic sales of $28.1 million, +25.3% compared to FY 4Q21. For the full fiscal year, the company generated $106.9 million, representing growth of 9.8% vs. the year prior.
The company's Novastep foot and ankle business continued its steady growth in the fourth quarter and now accounts for about 17% of...
Amplitude Surgical reported FY 4Q22 orthopedic sales of $28.1 million, +25.3% compared to FY 4Q21. For the full fiscal year, the company generated $106.9 million, representing growth of 9.8% vs. the year prior.
The company’s Novastep foot and ankle business continued its steady growth in the fourth quarter and now accounts for about 17% of Amplitude’s total revenue. As the business nears $20 million in annual revenue, it could represent a compelling acquisition opportunity for a larger player.
To that end, Amplitude launched a “strategic review of Novastep’s foot and ankle activity” in late June. The review’s goal is to maximize value creation for the company as a whole and could eventually lead to the divestment of Novastep.
One potential reason for the Novastep review could be Amplitude’s planned entry into robotics. In April, the company partnered with eCential Robotics to develop a robotic knee surgery solution. eCential’s current open system has partnered with multiple players in spine surgery. This partnership will add Amplitude’s proprietary Amplivision navigation and the latest alignment techniques.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $23.3 | $19.1 | $4.2 | 22.1% |
| Knees | $12.8 | $10.3 | $2.5 | 24% |
| Hips | $10.5 | $8.7 | $1.7 | 19.7% |
| Trauma | $4.8 | $3.4 | $1.5 | 43.8% |
| Total | $28.1 | $22.4 | $5.7 | 25.3% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $89.1 | $84.4 | $4.8 | 5.7% |
| Knees | $48.8 | $46.5 | $2.3 | 5% |
| Hips | $40.3 | $37.9 | $2.5 | 6.5% |
| Trauma | $17.8 | $13.1 | $4.7 | 36.2% |
| Total | $106.9 | $97.4 | $9.5 | 9.8% |
Orthopedic Sales by Geography
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $18.3 | $14.3 | $4.0 | 28% |
| International | $9.8 | $8.1 | $1.7 | 20.6% |
| Subsidiaries | $7.2 | $6.1 | $1.1 | 17.4% |
| Distributors | $2.7 | $2.1 | $0.6 | 30.1% |
| Total | $28.1 | $22.4 | $5.7 | 25.3% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $69.6 | $63.6 | $6.0 | 9.4% |
| International | $37.3 | $33.8 | $3.5 | 10.5% |
| Subsidiaries | $28.4 | $25.7 | $2.7 | 10.5% |
| Distributors | $8.9 | $8.1 | $0.8 | 10.5% |
| Total | $106.9 | $97.4 | $9.5 | 9.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
